早期子宫内膜癌辅助阴道近距离放疗联合化疗与盆腔放疗比较:按危险因素分析结局
基于美国国家癌症数据库(NCDB)纳入符合GOG 249标准的4602例早期子宫内膜癌患者,41%接受阴道近距离放疗联合化疗(VBT+CT),59%接受盆腔放疗(WPRT)。全队列中VBT+CT与生存改善相关,3年总生存率89.6% vs 87.8%(HR 1.24,95%CI 1.01-1.52,P=0.04);亚组分析显示浆液性组织学患者从VBT+CT获益,而无淋巴结清扫的高级别子宫内膜癌患者从EBRT获益。
要点
- 全队列VBT+CT与生存改善相关,3年OS 89.6% vs 87.8%(HR 1.24,95%CI 1.01-1.52,P=0.04)。
- 浆液性组织学患者从VBT+CT获益;排除浆液性组织学后两种治疗无生存差异。
- 无淋巴结清扫的高级别子宫内膜癌患者与EBRT相关的生存改善。
核心结论
- VBT+CT与早期浆液性癌患者更优的生存结局相关。
- 对于非浆液性组织学,治疗方式与生存差异无关,尽管无淋巴结清扫的高级别疾病患者从EBRT获益。
研究设计与样本
- 回顾性研究,使用美国国家癌症数据库(NCDB)中符合GOG 249纳入标准并接受VBT+CT或WPRT治疗的患者。
- 共纳入4602例患者,41%接受VBT+CT,59%接受WPRT。
- 采用Cox比例风险模型分析治疗类型及其他变量与总生存的关联,并根据高危病理、手术淋巴结采样和分级等危险因素进行亚组分析。
主要发现
- 全队列中VBT+CT与生存改善相关,3年总生存率89.6% vs 87.8%(HR 1.24,95%CI 1.01-1.52,P=0.04)。
- 亚组分析中,浆液性组织学患者从VBT+CT获益。
- 无淋巴结清扫的高级别子宫内膜癌患者与EBRT相关的生存改善。
- 排除浆液性组织学后,治疗类型与生存无差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To report on patterns of care as well as evaluate the two treatment regimens using a large retrospective hospital-based registry to identify possible subgroups of patients who may experience benefit with VBT + CT vs. EBRT. METHODS: Patients from the National Cancer Database (NCDB) were identified who met the inclusion criteria for GOG 249 and were treated with either VBT + CT or WPRT. Demographic, clinicopathologic, and treatment factors were collected. Association of treatment type and other variables with overall survival was analyzed using Cox proportional hazards model. Subset analyses were performed based on a variety of risk factors, including high risk pathologies, surgical nodal sampling, and grade. RESULTS: A total of 4,602 patients were included in the analysis, with 41% receiving VBT + CT and 59% receiving WPRT. For the entire cohort, VBT + CT was associated with improved survival, with 3-year overall survival 89.6% vs. 87.8% (hazard ratio 1.24, 95%CI 1.01-1.52, p = 0.04). On subset analysis, patients with serous histology experienced benefit with VBT + CT, while high-grade endometrial patients without lymph node dissection experienced improved survival associated with EBRT. After exclusion of serous histology, there was no survival difference associated with treatment type. CONCLUSIONS: VBT + CT was associated with superior survival outcomes in patients with early-stage serous carcinoma. For non-serous histology, treatment modality was not associated with a difference in survival, although patients with high-grade disease and no nodal dissection experienced benefit from EBRT.
引用
- Tatebe K, Hasan Y, Son CH, et al. Adjuvant vaginal brachytherapy and chemotherapy versus pelvic radiotherapy in early-stage endometrial cancer: Outcomes by risk factors. Gynecol Oncol. 2019. PMID: 31610885. doi:10.1016/j.ygyno.2019.09.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。